48 - "Unlocking the Power of AI & Modeling & Simulation in Modern Pharmaceutical Development"
Abstract:
The pharmaceutical industry is undergoing a rapid digital transformation, driven by the integration of advanced computational techniques like Artificial Intelligence (AI) and Modeling & Simulation (M&S) into drug development. At InSilicoMinds, we leverage our expertise in these areas to empower our clients and propel their pharmaceutical products towards success. Please join us for an informative session to explore how AI & M&S are accelerating traditional drug development and bringing safe and effective medicines to patients faster.
Drug Discovery:
- Demonstrate how AI-driven approaches can accelerate the identification of promising drug candidates, optimize their properties, and predict ADME/Tox profiles, reducing time and cost.
Drug Development.
- We will highlight the transformative role of M&S in formulation optimization, bioequivalence assessment, and clinical study design. All which contribute to increasing the likelihood of regulatory approval and commercial success.
Furthermore, we will discuss the growing emphasis placed by global regulators (like the FDA & EMA) on the use of in silico approaches to support decision-making and the reduction of experimental burden. We will share a few experiences and case studies to demonstrate how we help pharmaceutical companies navigate modern drug development with greater efficiency, reduced risk, and accelerated timelines.
Short Bios:
Nirnith Devireddy:
The Founder and CEO of InSilicoMinds (Ikiminds Pvt Ltd.). Nirnith is a seasoned tech entrepreneur with over a decade of experience. He also Co-founded Anipanion, the world’s leading veterinary virtual care platform.
He has completed his Executive Education at Harvard Medical School in Implementing AI Solutions in Healthcare & has a BBA from Babson College with a concentration in Technology, Entrepreneurship, & Design.
Nirnith is an active speaker and thought leader within the Pharmaceutical Industry in India where he shares his insights and experiences at leading industry conferences such as ISCR, BioAsia, SAC-AACP to name a few. He is the Co-Chair of the Avicenna Alliance AI Task Force and an active proponent of AI & M&S in the Pharmaceutical Industry.
Pranav Karmwar:
Dr. Pranav is a seasoned AI, Modeling & Simulation professional in the pharmaceutical industry with over a decade of experience in various MNCs. His expertise lies in biopharmaceutics control strategies and modeling and simulation activities for the development of R&D projects. Pranav led the development and optimization of biopharmaceutical products using modeling and simulation techniques, ensuring project goals are met on time and within budget. He has collaborated with cross-functional teams to develop and implement successful product development strategies and overseen the submission of regulatory documents to ensure compliance with applicable regulations and guidelines.
At InSilicoMinds, Dr. Karmwar oversees the company's scientific strategy, driving the development of innovative in silico solutions that address the evolving needs of the pharmaceutical industry. He is a passionate advocate for the transformative power of computational approaches and has been instrumental in forging strong collaborations with industries and regulatory agencies, such as the FDA and EMA, to advance the acceptance and integration of in silico frameworks.